Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AdPEDF
- Development stage
- Phase 1
- Lead developer
- Precigen
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intravitreal
01
Overview
AdPEDF is a gene therapy that uses an adenoviral vector to deliver the human pigment epithelium-derived factor (PEDF) gene into ocular tissues. PEDF is a naturally occurring antiangiogenic protein that inhibits factors such as fibroblast growth factor, platelet-derived growth factor, interleukin-8, and vascular endothelial growth factor. The therapy aims to treat neovascular (wet) age-related macular degeneration (AMD) by reducing abnormal blood vessel growth in the retina. After intravitreal injection of the viral vector carrying the PEDF gene, retinal cells produce PEDF protein locally for several months. Early clinical studies have shown that AdPEDF was well tolerated and may provide antiangiogenic activity in patients with advanced neovascular AMD[6][8].
- Brand names
- AdPEDF
- Other names
- adenoviral vector-delivered pigment epithelium-derived factoradenoviral PEDF gene therapy
02
Targets
VEGFA (Vascular endothelial growth factor A)PEDF (Pigment epithelium-derived factor)FGF (Fibroblast growth factor 6)PDGF (Platelet-derived Growth Factor family)IL8 (C-X-C Motif Chemokine Ligand 8)
Beyond the preview
Go deeper on AdPEDF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AdPEDF.